Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A SubStudy of the Cmrg-007 Trial

被引：0

作者：

Louzada, Martha L. ^{[1
]}

Reece, Donna E. ^{[2
]}

McCurdy, Arleigh ^{[3
]}

Kotb, Rami ^{[4
]}

Othman, Ibraheem ^{[5
]}

Mian, Hira ^{[6
]}

Lin, Toni ^{[7
]}

Chu, Michael P. ^{[8
]}

White, Darrell ^{[9
,10
]}

Parkin, Stephen ^{[11
]}

Gul, Engin ^{[12
]}

Khan, Aniba ^{[12
]}

Trudel, Suzanne ^{[13
]}

机构：

[1] London Hlth Sci Ctr, London, ON, Canada

[2] Canadian Myeloma Res Grp, Toronto, ON, Canada

[3] Ottawa Hosp, Ottawa, ON, Canada

[4] Canc Care Manitoba, Winnipeg, MB, Canada

[5] Allan Blair Canc Ctr, Regina, SK, Canada

[6] McMaster Univ, Hamilton, ON, Canada

[7] Western Univ, London, ON, Canada

[8] Alberta Hlth Serv, Edmonton, AB, Canada

[9] Dalhousie Univ, Halifax, NS, Canada

[10] QEII Hlth Sci Ctr, Halifax, NS, Canada

[11] Vancouver Gen Hosp, Vancouver, BC, Canada

[12] Canadian Myeloma Res Grp, Vaughan, ON, Canada

[13] McLaughlin Ctr Mol Med, Toronto, ON, Canada

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174993

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 4 条

[1] Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Fotiou, Despina
Kanellias, Nikolaos
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Papaiakovou, Evangelos Eleutherakis
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD, 2022, 140 : 7267 - 7268
[2] Ocular adverse events and functional impact in transplant ineligible, newly diagnosed multiple myeloma patients treated with belantamab mafodotin, lenalidomide and dexamethasone in BelaRd trial
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vassiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S102 - S103
[3] An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Douvali, Maria
Gkolfinopoulos, Stavros
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD, 2023, 142
[4] Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Douvali, Maria
Gkolfinopoulos, Stavros
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD, 2023, 142

← 1 →